# Hydralazine as Demethylating Agent in Breast Cancer

> **NCT00575978** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Arkansas**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Hydralazine

## Key facts

- **NCT ID:** NCT00575978
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IRB request
- **Last updated:** 2015-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575978, "Hydralazine as Demethylating Agent in Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00575978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*